Medicare AdvantageCoverageLow impact
MA08.094c, Voretigene Neparvovec-rzyl (Luxturna®)
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.094c for Voretigene Neparvovec-rzyl (Luxturna®), a gene therapy medication, has been reissued and is effective October 29, 2025. This pharmacy policy update may affect coverage criteria, prior authorization requirements, or billing procedures for this specialized ophthalmology treatment.
Action Required
By October 29, 2025: Billing team should review the complete policy details at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for Luxturna® (Voretigene Neparvovec-rzyl). Update billing protocols if new requirements are specified in the full policy.